T1	intervention 0 27	Dose-intensified epirubicin
T2	control 35 76	standard-dose epirubicin/cyclophosphamide
T3	eligibility 96 155	breast cancer patients with 10 or more positive lymph nodes
T4	outcome 767 805	5-year event-free survival (EFS) rates
T5	iv-bin-percent 811 816	47.7%
T6	intervention-participants 485 488	202
T7	control-participants 669 672	209
T8	cv-bin-percent 873 878	45.9%
T9	outcome 951 954	EFS
T12	outcome 1034 1050	overall survival
